{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:19:25Z","timestamp":1780373965793,"version":"3.54.1"},"reference-count":57,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Esophageal cancer (EC) is the eighth most common cancer and the sixth most common cause of death worldwide. Esophageal squamous cell carcinoma (ESCC) comprises the majority of esophageal cancers globally, and 5-Fluorouraci (5-FU) is one of the commonly used chemotherapeutics for this type of cancer. Chemoresistance to drugs is a main obstacle in the successful treatment of this malignancy. Methods: In this study, we used the CRISPR\/Cas9 screening method to determine the target gene related to 5-FU drug resistance in esophageal cancer. Results: Our research findings indicate that the loss of PFKFB3 can increase the resistance of different human esophageal squamous cell carcinoma cell lines to 5-FU through various pathways. Specifically, in KYSE-70 cells, loss of PFKFB3 can induce epithelial\u2013mesenchymal transition (EMT) and prolong the S phase of the cell cycle, allowing cancer cells to evade the effects of 5-FU and develop resistance. In the KYSE-270 and KYSE-150 cell lines, loss of PFKFB3 can upregulate the expression of Slug and Mcl-1, indirectly regulate Chk1 and promote its autophosphorylation, which in turn inhibits apoptosis, thus counteracting the effects of 5-FU. Conclusions: Our research not only enriches our understanding of the biological characteristics of different ESCC cell lines but also provides new clinical insights for future personalized treatments. Assessing the status of PFKFB3 can help predict resistance to 5-FU in ESCC patients with different genetic backgrounds, allowing for more precise treatment planning. This personalized approach has the potential to improve treatment efficacy, reduce unnecessary drug use and side effects, and ultimately improve patient survival rates and quality of life.<\/jats:p>","DOI":"10.3390\/cancers17101637","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T09:13:38Z","timestamp":1747041218000},"page":"1637","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CRISPR\/Cas9 Screening Highlights PFKFB3 Gene as a Major Contributor to 5-Fluorouracil Resistance in Esophageal Cancer"],"prefix":"10.3390","volume":"17","author":[{"given":"Feng","family":"Xue","sequence":"first","affiliation":[{"name":"Department of Surgery, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU) and Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Surgery, Juraklinik Sche\u00dflitz, 96110 Sche\u00dflitz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU) and Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuman","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Surgery, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU) and Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0494-7117","authenticated-orcid":false,"given":"Nathalie","family":"Britzen-Laurent","sequence":"additional","affiliation":[{"name":"Department of Surgery, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU) and Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Li","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Medicine 1, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU) and Universit\u00e4tsklinikum Erlangen, 91052 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gr\u00fctzmann","sequence":"additional","affiliation":[{"name":"Department of Surgery, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU) and Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2537-5824","authenticated-orcid":false,"given":"Christian","family":"Krautz","sequence":"additional","affiliation":[{"name":"Department of Surgery, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU) and Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7968-3283","authenticated-orcid":false,"given":"Christian","family":"Pilarsky","sequence":"additional","affiliation":[{"name":"Department of Surgery, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU) and Universit\u00e4tsklinikum Erlangen, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannova","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1759-7714.14745","article-title":"Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040","volume":"14","author":"Liu","year":"2023","journal-title":"Thorac. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00018-022-04131-6","article-title":"Molecular mechanisms associated with chemoresistance in esophageal cancer","volume":"79","author":"Nasciutti","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e074962","DOI":"10.1136\/bmj-2023-074962","article-title":"Advances in diagnosis and management of cancer of the esophagus","volume":"385","author":"Deboever","year":"2024","journal-title":"BMJ"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ghafouri-Fard, S., Abak, A., Tondro Anamag, F., Shoorei, H., Fattahi, F., Javadinia, S.A., Basiri, A., and Taheri, M. (2021). 5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.658636"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s10388-025-01113-y","article-title":"Investigating the synergistic effects of immunochemotherapy in esophageal squamous cell carcinoma","volume":"22","author":"Okui","year":"2025","journal-title":"Esophagus"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2174\/0113816128301465240517065848","article-title":"CRISPR\/Cas9 Technology: A Novel Approach to Obesity Research","volume":"30","author":"Khademi","year":"2024","journal-title":"Curr. Pharm. Des."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s43586-022-00098-7","article-title":"High-content CRISPR screening","volume":"2","author":"Bock","year":"2022","journal-title":"Nat. Rev. Methods Prim."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/s41596-024-00995-z","article-title":"Integrating genome-wide CRISPR screens and in silico drug profiling for targeted antidote development","volume":"19","author":"Wang","year":"2024","journal-title":"Nat. Protoc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","article-title":"Genome-scale CRISPR-Cas9 knockout screening in human cells","volume":"343","author":"Shalem","year":"2014","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e614","DOI":"10.1002\/cpz1.614","article-title":"CRISPR-Suppressor Scanning for Systematic Discovery of Drug-Resistance Mutations","volume":"2","author":"Ngan","year":"2022","journal-title":"Curr. Protoc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-0716-2513-2_12","article-title":"Identification of Drug Resistance Mechanisms Using Genome-Wide CRISPR-Cas9 Screens","volume":"2535","author":"MacLeod","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12943-022-01565-1","article-title":"CRISPR\/Cas9 and next generation sequencing in the personalized treatment of Cancer","volume":"21","author":"Selvakumar","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1158\/1078-0432.CCR-20-3365","article-title":"Mutations in the IFNgamma-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment","volume":"27","author":"Nguyen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Li, W., Koster, J., Xu, H., Chen, C.H., Xiao, T., Liu, J.S., Brown, M., and Liu, X.S. (2015). Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol., 16.","DOI":"10.1186\/s13059-015-0843-6"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"D848","DOI":"10.1093\/nar\/gkaa809","article-title":"CRISP-view: A database of functional genetic screens spanning multiple phenotypes","volume":"49","author":"Cui","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100796","DOI":"10.1016\/j.drup.2021.100796","article-title":"Anticancer drug resistance: An update and perspective","volume":"59","author":"Nussinov","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the mechanisms and challenges of cancer drug resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1038\/s41467-022-30582-3","article-title":"Mutational signatures are markers of drug sensitivity of cancer cells","volume":"13","author":"Levatic","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1535-7163.MCT-08-0716","article-title":"Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance","volume":"8","author":"Humeniuk","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Niu, Y., Fan, X., Wang, Y., Lin, J., Hua, L., Li, X., Qian, R., and Lu, C. (2022). Genome-wide CRISPR Screening Reveals Pyrimidine Metabolic Reprogramming in 5-FU Chronochemotherapy of Colorectal Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.949715"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17044","DOI":"10.1038\/sigtrans.2017.44","article-title":"Roles of PFKFB3 in cancer","volume":"2","author":"Shi","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kotowski, K., Rosik, J., Machaj, F., Supplitt, S., Wiczew, D., Jablonska, K., Wiechec, E., Ghavami, S., and Dziegiel, P. (2021). Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development\/Progression, and Potential as Therapeutic Targets. Cancers, 13.","DOI":"10.3390\/cancers13040909"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e23578","DOI":"10.1002\/jcla.23578","article-title":"Mir-488 alleviates chemoresistance and glycolysis of colorectal cancer by targeting PFKFB3","volume":"35","author":"Deng","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10555-022-10027-5","article-title":"Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux","volume":"41","author":"Jones","year":"2022","journal-title":"Cancer Metastasis Rev."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lypova, N., Dougherty, S.M., Lanceta, L., Chesney, J., and Imbert-Fernandez, Y. (2021). PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs. Cells, 10.","DOI":"10.3390\/cells10071679"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9877","DOI":"10.1007\/s11033-022-07513-y","article-title":"The role of PFKFB3 in maintaining colorectal cancer cell proliferation and stemness","volume":"49","author":"Yan","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12020-024-03725-3","article-title":"PFKFB3 facilitates cell proliferation and migration in anaplastic thyroid carcinoma via the WNT\/beta-catenin signaling pathway","volume":"85","author":"Deng","year":"2024","journal-title":"Endocrine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neo.2020.12.009","article-title":"Glycolysis-induced drug resistance in tumors-A response to danger signals?","volume":"23","author":"Marcucci","year":"2021","journal-title":"Neoplasia"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Sethy, C., and Kundu, C.N. (2021). 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed. Pharmacother., 137.","DOI":"10.1016\/j.biopha.2021.111285"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/1535-7163.MCT-19-0918","article-title":"Synthetic Lethality with Trifluridine\/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma","volume":"19","author":"Ohashi","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e788","DOI":"10.1002\/mco2.788","article-title":"Targeting the DNA damage response in cancer","volume":"5","author":"Federica","year":"2024","journal-title":"MedComm"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: Lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1016\/j.febslet.2012.09.048","article-title":"DNA damage-induced CHK1 autophosphorylation at Ser296 is regulated by an intramolecular mechanism","volume":"586","author":"Okita","year":"2012","journal-title":"FEBS Lett."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Tantawy, S.I., Timofeeva, N., Sarkar, A., and Gandhi, V. (2023). Targeting MCL-1 protein to treat cancer: Opportunities and challenges. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1226289"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Hafezi, S., and Rahmani, M. (2021). Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13061292"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41419-022-04810-z","article-title":"Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa\/Bim\/Mcl-1\/p-Chk1 axis","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Long, S., Wang, J., Weng, F., Pei, Z., Zhou, S., Sun, G., and Xiang, D. (2022). ECM1 regulates the resistance of colorectal cancer to 5-FU treatment by modulating apoptotic cell death and epithelial-mesenchymal transition induction. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1005915"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bbrc.2021.04.009","article-title":"SPARC enhances 5-FU chemosensitivity in gastric cancer by modulating epithelial-mesenchymal transition and apoptosis","volume":"558","author":"Ma","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41417-022-00490-1","article-title":"GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K\/PDK1\/ROCK1 pathway","volume":"29","author":"Tiu","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1002\/cam4.3933","article-title":"NOTCH3 limits the epithelial-mesenchymal transition and predicts a favorable clinical outcome in esophageal cancer","volume":"10","author":"Matsuura","year":"2021","journal-title":"Cancer Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.semcancer.2023.10.001","article-title":"Transcriptional regulation of EMT transcription factors in cancer","volume":"97","author":"Saitoh","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/med.21948","article-title":"Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds","volume":"43","author":"Ang","year":"2023","journal-title":"Med. Res. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1158\/0008-5472.CAN-13-2591","article-title":"Slug promotes survival during metastasis through suppression of Puma-mediated apoptosis","volume":"74","author":"Kim","year":"2014","journal-title":"Cancer Res."},{"key":"ref_50","first-page":"23","article-title":"Effect of modulation of epithelial-mesenchymal transition regulators Snail1 and Snail2 on cancer cell radiosensitivity by targeting of the cell cycle, cell apoptosis and cell migration\/invasion","volume":"17","author":"Assani","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s12032-010-9652-7","article-title":"Slug regulates proliferation and invasiveness of esophageal adenocarcinoma cells in vitro and in vivo","volume":"28","author":"Zhang","year":"2011","journal-title":"Med. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"12224","DOI":"10.1093\/nar\/gkad952","article-title":"TATDN2 resolution of R-loops is required for survival of BRCA1-mutant cancer cells","volume":"51","author":"Jaiswal","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e4479","DOI":"10.1002\/pro.4479","article-title":"Computed cancer interactome explains the effects of somatic mutations in cancers","volume":"31","author":"Zhang","year":"2022","journal-title":"Protein Sci."},{"key":"ref_55","unstructured":"Hardison, K.L., Hawk, T.M., Bouley, R.A., and Petreaca, R.C. (2022). KAT5 histone acetyltransferase mutations in cancer cells. microPubl. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1039\/D2SC05709C","article-title":"AlphaFold accelerates artificial intelligence powered drug discovery: Efficient discovery of a novel CDK20 small molecule inhibitor","volume":"14","author":"Ren","year":"2023","journal-title":"Chem. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/10\/1637\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:31:20Z","timestamp":1760031080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/10\/1637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cancers17101637"],"URL":"https:\/\/doi.org\/10.3390\/cancers17101637","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]}}}